Cyient DLM (CYIENTDLM)
Fast GrowerFairStock Score: 40/100 — MIXED
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 1/2 · Dividend: 0/1
Key Financials
| Current Price | ₹696.65 |
| Market Cap | ₹5,528.92 Cr |
| P/E Ratio | 67.57 |
| ROCE | 10.99% |
| ROE | 7.21% |
| Dividend Yield | 0% |
| Profit Growth | 48.15% |
| Debt/Equity | 0.17 |
| Sales Growth | 34.48% |
| Free Cash Flow | ₹2,13,57,125.12 Cr |
| Promoter Holding | 52.12% |
| 52-Week Range | ₹265.2 — ₹1,060.1 |
| Sector | Industrial Manufacturing |
| Book Value | ₹127.53 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Let me start with what I value: a business I understand, a strong balance sheet, and a price that leaves room for error. Cyient DLM operates in industrial products. The first thing I see is a sharp revenue decline. Sales growth is minus 31.71%. Profit growth of 2.18% is positive, but with sales falling that hard, I have to question earnings quality. The latest quarter shows sales of ₹303 crore and net profit of ₹11 crore, a thin margin of about 3.6%. The market capitalizes this company at ₹2,481 crore and asks me to pay a P/E of 30.30 and a P/B of 3.21. For a business earning an ROE of only 7.21%, paying more than three times book value is not a bargain. At ₹381.50, against book value of ₹118.89, I need either much higher future returns or a speculative multiple expansion. Graham would say the margin of safety is missing. The balance sheet is the one bright spot: debt/equity of 0.17 is conservative, and the Piotroski F-score of 6/9 suggests no immediate distress. Promoter holding of 52.12% is a positive alignment. ROCE of 10.99% is reasonable but not exceptional. There is no dividend; I receive no income while waiting. The PEG of 13.90 confirms the price is far too rich for the company’s growth. The reported free cash flow of ₹213.57 lakh crore appears to be a data error; I cannot rely on it for valuation. With a risk score of 14/100, the signal is clearly cautious. This looks like a cyclical business, possibly in a downcycle. The stock has fallen from ₹737.55, but a falling price alone is not a reason to buy. I would wait for evidence of sustained sales recovery and a meaningful improvement in returns on capital before considering Cyient DLM.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer